The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Subscribe To Our Newsletter & Stay Updated
